Assesment of TDApp1 an eHelath Tool to Make Therapeutic Recommendations for Patients With ADHD
- Conditions
- Attention Deficit-hyperactivity Disorder
- Registration Number
- NCT04228094
- Lead Sponsor
- Universitat de Girona
- Brief Summary
This is a 3-week open label, one group study to determine the agreement between the pharmacological treatment recommended by TDApp1 and the interventions recommended by relevant clinical practice guidelines.
- Detailed Description
Clinical practice guidelines (CPGP) allow optimizing medical decisions and health care based on the best evidence available. Nevertheless, CPGs have several limitations. First, many GPC are outdated shortly after their publication. Second, CPG recommendations are often not applicable to many patients treated in clinical practice. Most CPGs do not make recommendations for patients with a mild disorder or for complex patients with comorbiditie. Another limitation is that patients involvement in CPGs development is still poor.
We aim to develop and assess TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder.
A 3-week, one group, open label study will be conducted. Fifty-five patients aged 6-65 with ADHD will use TDApp1. The therapeutic recommendations made by the TDApp1 and by relevant CPG will be compared. Concordance in the recommendations will be studied. Effectiveness, safety, changes in physical activity and satisfaction will be investigated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
- Male and female patients ages 6-65
- A diagnosis of DSM-V ADHD based on clinical assessment
- Patients under adequate therapeutic treatment or requiring minor adjustments
- Patients lacking an electronic device (mobile phone, tablet,...) with internet access
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment recommended/prescribed 4 days Treatment recommended/prescribed consists on the treatment recommended to the patient with ADHD by TDApp1 and the actual treatment prescribed by the investigator to this patient.
- Secondary Outcome Measures
Name Time Method Adverse events 3 weeks The incidence of adverse events will be collected by means of a questionnaire
Patient/parent satisfaction with the treatment prescribed 3 weeks Satisfaction of the patients or their parents with the prescribed treatment. This outcome will be collected by means of visual analogic scale that has been developed for this study. Score ranges from 1 to 9. Higher scores indicate greater satisfaction.
Physical activity 3 weeks The physical activity will be measured by means of ActiGraph wGT3X-BT that records continuous physical activity and sleep/wake information.
Patient/parent satisfaction with the participation in the health decision-making process 3 weeks Satisfaction of the patients or their parents with their participation in the health decision-making process. This outcome will be collected by means of visual analogic scale that has been developed for this study. Score ranges from 1 to 9. Higher scores indicate greater satisfaction.
ADHD symptom severity 3 weeks ADHD symptom severity will be assessed with the self-rated, 18-item, DSM V (in children and adolescents) or IV-TR (in adults) -based Rating Scale. Total score ranges from 0 to 54. Higher total scores indicate greater illness severity.
Patient/parent satisfaction with TDApp1 3 weeks The satisfaction of the patients or their parents with the educational material provided, and the usability and simplicity of TDApp1. This outcome will be collected by means of visual analogic scale that has been developed for this study. Score ranges from 1 to 9. Higher scores indicate greater satisfaction.
Trial Locations
- Locations (1)
Institut d'Assitència Sanitària
🇪🇸Girona, Catalonia, Spain